Use of Protein Arginine Methyltransferase Inhibitors in Gliomas.

Abstract

Gliomas are a type of CNS tumors. Protein arginine methyltransferases (PRMTs) play important epigenetic regulatory roles in various cancers, including gliomas, by regulating DNA repair and cellular signaling pathways. Recent studies have also identified overexpression of PRMTs in gliomas and have shown that it is associated with tumor progression and resistance to conventional therapies. Targeting PRMTs has shown promising preclinical results demonstrating the potential to disrupt tumor growth, enhance DNA damage responses, and improve the sensitivity of gliomas to radiotherapy and temozolomide. In this review, we focus on the translational and clinical relevance of PRMT inhibitors in glioma subtypes, highlighting their latest clinical developments and ongoing clinical trials. Unlike previous reviews, our article provides an updated synthesis of clinical data, discusses challenges and opportunities in clinical translation, and suggests future directions for integrating PRMT inhibitors into glioma therapy.